These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 24557923)

  • 1. Cisplatin-induced bradycardia and the importance of the QT interval.
    Schlumbrecht MP; Hehr K
    J Oncol Pharm Pract; 2015 Apr; 21(2):157-60. PubMed ID: 24557923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin induced bradycardia.
    Darling HS
    Int J Cardiol; 2015 Mar; 182():304-6. PubMed ID: 25585374
    [No Abstract]   [Full Text] [Related]  

  • 3. Digital Holter measurement of QT prolongation in ziprasidone overdose.
    Berling I; Isbister GK; Calver L; Clunas S
    Clin Toxicol (Phila); 2011 Aug; 49(7):694-6. PubMed ID: 21819290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Slower heart rate and altered rate dependence of ventricular repolarization in patients with lone atrial fibrillation.
    Maury P; Caudron G; Bouisset F; Fourcade J; Duparc A; Mondoly P; Rollin A; Hascoët S; Detis N; Cardin C; Delay M; Lairez O; Roncalli J; Galinier M; Carrié D; Elbaz M; Ferrières J; Fauvel JM; Zimmermann M
    Arch Cardiovasc Dis; 2013 Jan; 106(1):12-8. PubMed ID: 23374967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preferred QT correction formula for the assessment of drug-induced QT interval prolongation.
    Chiladakis J; Kalogeropoulos A; Arvanitis P; Koutsogiannis N; Zagli F; Alexopoulos D
    J Cardiovasc Electrophysiol; 2010 Aug; 21(8):905-13. PubMed ID: 20233271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A rare entity: Recurrent cisplatin-induced bradycardia.
    Sagcan F; Citak EC; Karpuz D; Alakaya M
    J Cancer Res Ther; 2020; 16(3):699-700. PubMed ID: 32719297
    [No Abstract]   [Full Text] [Related]  

  • 7. Recurrent asymptomatic bradycardia episodes after cisplatin infusion.
    Altundağ O; Celik I; Kars A
    Ann Pharmacother; 2001 May; 35(5):641-2. PubMed ID: 11346072
    [No Abstract]   [Full Text] [Related]  

  • 8. Perceptions of cisplatin-related toxicity among ovarian cancer patients and gynecologic oncologists.
    Calhoun EA; Bennett CL; Peeples PA; Lurain JR; Roland PY; Weinstein JM; Fishman DA
    Gynecol Oncol; 1998 Dec; 71(3):369-75. PubMed ID: 9887233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of resveratrol to improve the effectiveness of cisplatin and doxorubicin: study in human gynecologic cancer cell lines and in rodent heart.
    Rezk YA; Balulad SS; Keller RS; Bennett JA
    Am J Obstet Gynecol; 2006 May; 194(5):e23-6. PubMed ID: 16647892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Letter: Brady-tachy syndrome with prolonged retrograde conduction due to digitalis and propranolol intoxication.
    Abraham AS; Menczel J
    Chest; 1975 May; 67(5):627-8. PubMed ID: 1126215
    [No Abstract]   [Full Text] [Related]  

  • 12. Old habits die hard: the quest for correct(ed) QT interval measurements.
    Husser D; Hindricks G
    J Cardiovasc Electrophysiol; 2010 Aug; 21(8):914-5. PubMed ID: 20626523
    [No Abstract]   [Full Text] [Related]  

  • 13. Cisplatin-induced bradycardia: Cardiac toxicity or cardiac hypersensitivity and Kounis syndrome?
    Kounis NG; Cervellin G; Lippi G
    Int J Cardiol; 2016 Jan; 202():817-8. PubMed ID: 26476038
    [No Abstract]   [Full Text] [Related]  

  • 14. Nifekalant enlarged the transmural activation-recovery interval difference as well as the peak-to-end interval on surface ECG in a patient with short-QT syndrome.
    Chinushi M; Sato A; Izumi D; Furushima H
    J Cardiovasc Electrophysiol; 2012 Aug; 23(8):877-80. PubMed ID: 22494577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gitelman-like syndrome after cisplatin therapy: a case report and literature review.
    Panichpisal K; Angulo-Pernett F; Selhi S; Nugent KM
    BMC Nephrol; 2006 May; 7():10. PubMed ID: 16723030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse effects using combined rate-slowing antihypertensive agents.
    Handler J
    J Clin Hypertens (Greenwich); 2011 Jul; 13(7):529-32. PubMed ID: 21762367
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of mefloquine on electrocardiographic changes in uncomplicated falciparum malaria patients.
    Laothavorn P; Karbwang J; Na Bangchang K; Bunnag D; Harinasuta T
    Southeast Asian J Trop Med Public Health; 1992 Mar; 23(1):51-4. PubMed ID: 1523478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unusual cause of wide complex tachycardia during coronary angiography.
    Kansal MM; Vidovich MI
    Cardiovasc Revasc Med; 2009; 10(1):60-1. PubMed ID: 19159858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute arrhythmogenicity of first-dose chemotherapeutic agents in children.
    Massin MM; Dresse MF; Schmitz V; Hoyoux C; Chantraine JM; Lepage P
    Med Pediatr Oncol; 2002 Aug; 39(2):93-8. PubMed ID: 12116056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac conduction disturbance due to prallethrin (pyrethroid) poisoning.
    Bhaskar EM; Moorthy S; Ganeshwala G; Abraham G
    J Med Toxicol; 2010 Mar; 6(1):27-30. PubMed ID: 20195813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.